About Exo Therapeutics
Exo Therapeutics is a company focused on the medical sector, specifically in the domain of drug development. The company's main service is the development of drugs that modulate enzyme activity, with a particular focus on oncology and inflammation. These drugs are designed to unlock intractable drug targets with precision and potency. It was founded in 2018 and is based in Watertown, Massachusetts.
Research containing Exo Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Exo Therapeutics in 1 CB Insights research brief, most recently on Jan 19, 2021.
Latest Exo Therapeutics News
May 23, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exo Therapeutics announces its lead program directed against TBK1, and the appointment of Alexandra Joseph, PhD, as Executive Vice President, Biology.
Exo Therapeutics Frequently Asked Questions (FAQ)
When was Exo Therapeutics founded?
Exo Therapeutics was founded in 2018.
Where is Exo Therapeutics's headquarters?
Exo Therapeutics's headquarters is located at 480 Arsenal Way, Watertown.
What is Exo Therapeutics's latest funding round?
Exo Therapeutics's latest funding round is Series B.
How much did Exo Therapeutics raise?
Exo Therapeutics raised a total of $103M.
Who are the investors of Exo Therapeutics?
Investors of Exo Therapeutics include Novartis Venture Funds, CRV, 6 Dimensions Capital, Newpath Partners, BVF Partners and 6 more.